IVF Services Global Market Report 2023 – By Cycle Type (Fresh IVF Cycles(Nondonor), Thawed IVF Cycles (Nondonor), Donor Egg IVF Cycles), By Service Provider (Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes), By EndUser (Fertility Clinics, Hospitals & Other Settings) – Market Size, Trends, And Global Forecast 2023-2032

Fertility treatment is a medical procedure intended to increase the chances of conceiving a child. These services are used to increase the chances of bearing a child. The main types of services in fertility services are fresh non-donor, frozen non-donor, egg and embryo banking, fresh donor, and frozen donor. Donor eggs are collected and immediately ertilized with the male partner’s sperm in a fresh donor egg IVF cycle, with the developing fresh embryos being delivered to the recipient. The leftover embryos can be preserved and used in future frozen embryo transfers. The different procedures include assisted reproductive technology (ART), in-vitro fertilization, artificial insemination and is used by both male, female. The global fertility services market is segmented - 1) By Procedure: Assisted Reproductive Technology (ART), In-Vitro Fertilization, Artificial Insemination 2) By Service: Fresh Non-Donor, Frozen Non-Donor, Egg and Embryo Banking, Fresh Donor, Frozen Donor 3) By Application: Male, Female The global fertility services market size will grow from $47.17 billion in 2022 to $54.12 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global fertility services is expected to grow to $90.14 billion in 2027 at a CAGR of 13.6%. Growing infertility rates are anticipated to boost the demand for fertility services during the forecast period. Various social and environment-related factors such as lifestyle changes including obesity, stress or depression, and high consumption of alcohol contribute to a surge in infertility rates, thereby generating the high requirement for fertility services. For example, in 2020, according to NPR, a US-based non-profit media organization, there were 4% fewer babies born in the United States in 2020 than in 2019. The preliminary figures showed that the overall fertility rate hit yet another record low, at 55.8 births per 1,000 women aged 15 to 44. Thus, growing infertility rates will drive the demand for fertility services market. Major players in the fertility services market are Merck KGaA, Care Fertility, INVO Bioscience, Vitrolife, Monash IVF Group, Carolinas Fertility Institute, IntegraMed, Inc., New Hope Fertility Centre and Apollo Hospitals Enterprise Ltd. The high cost of fertility services is expected to limit the growth of the fertility services market. The cost of in-vitro fertilization (IVF) primarily depends on infertility workup and varies from person to person. For instance, the average cost of one in-vitro fertilization (IVF) cycle is $12,000. The range of cost involved in one IVF cycle can be between $10,000 and $15,000, which excludes the cost of medication which may be as low as $1,500 or as high as $3,000 per cycle. The IVF cost is continuously rising attributing to modern diagnostic tests and various treatment methods such as hysteroscopy, IUI, and laparoscopy being used to facilitate and aid infertility treatment cost. Therefore, the high cost of fertility treatment is to act as a major challenge for the development of the fertility services market. Companies in the fertility services market have witnessed significant growth in the number of research collaborations as well as research funding approvals. Key companies operating in the market are projected to increase their R&D expenditure to introduce new advanced techniques and drugs used for fertility treatments. For instance, in October 2022, Maven Clinic, a US-based company specializing in telemedicine-based virtual clinic for women's and family health, collaborated with Indira IVF. The collaboration aimed at providing access to Maven members in India to Indira IVF's high-quality clinical care, other perks, and the best virtual family-building care available through the Maven platform. Indira IVF is an India-based infertility speciality clinic chain. Furthermore, in February 2021, CooperSurgical, a US-based company specializing in women’s health care solutions, collaborated with Virtus Health. The collaboration aimed at emphasizing on digitalization, cryogenics, and reproductive genetics, the cooperation will lead initiatives to assist patients' fertility journeys, including those who require egg, sperm, or embryo donations. Virtus Health is an Australia-based company specializing in fertility services. In December 2021, CooperCompanies, a US-based company specializing in women’s healthcare solutions, acquired Generate Life Sciences for $1.6 billion. Through this acquisition, CooperSurgical offers an even stronger selection of fertility centres and OB/GYNs. Generate Life Sciences is a US-based provider of donor eggs and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage. Western Europe was the largest region in the fertility services market in 2022. North America was the second largest region in global fertility services market share. The regions covered in the global fertility services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The fertility services market includes revenues earned by entities by providing artificial insemination, and intrauterine insemination. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The fertility services market research report is one of a series of new reports from The Business Research Company that provides fertility services market statistics, including fertility services industry global market size, regional shares, competitors with a fertility services market share, detailed fertility services market segments, market trends and opportunities, and any further data you may need to thrive in the fertility services industry. This fertility services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fetal bovine serum refers to a typical element of animal cell culture media that is utilised to support the growth of eukaryotic cells cultured in vitro. It is obtained by harvesting bovine foetuses from pregnant cows who were about to be slaughtered. FBS is frequently obtained with a cardiac puncture without the use of any type of anaesthesia. The main types of fetal bovine serum are charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell, others. Charcoal-stripped fetal bovine serum has activated carbon that helps lower levels of lipophilic compounds such as hormones, growth factors, and steroids and is used to conduct receptor or estrogen related studies. Dialyzed fetal bovine serum has reduced concentration of low molecular weight components such as nucleotides, amino acids, hormones, salts and various small proteins in serum and is used in cell culture systems requiring a more defined environment of small molecules. Exosome depleted fetal bovine serum isolates exosomes from cultured cells without the complication of bovine exosomes that are present in conventional FBS and is used for research on exosomes. The fetal bovine serum is used in drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics, others. Fetal bovine serum is used in various sectors including research and academic institutes, biotechnology and pharmaceutical industry, others. The global fetal bovine serum market is segmented - 1) By Product: Charcoal Stripped, Chromatographic, Dialyzed Fetal Bovine Serum, Exosome Depleted, Stem Cell, Other Products 2) By Application: Drug Discovery, Cell Culture Media, In Vitro Fertilization, Human and Animal Vaccine Production, Diagnostics, Other Applications 3) By End-User: Research and Academic Institutes, Biotechnology and Pharmaceutical Industry, Other End-Users The global fetal bovine serum market size will grow from $1010 million in 2022 to $1067.44 million in 2023 at a compound annual growth rate (CAGR) of 5.7% . The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the fetal bovine serum is expected to grow to $1419.98 million in 2027 at a CAGR of 7.4% . The increase in demand for biopharmaceuticals is expected to drive the growth of the fetal bovine serum market in the forecast period. A biopharmaceutical is a medicinal product that is derived from biological sources such as animals, humans, and microorganisms using biotechnology. Fetal bovine serum (FBS) is the most widely used substitute for animal cell culture media. Pharmaceutical firms, diagnostic laboratories, and researchers rely heavily on FBS for much of their cell culture requirements in biologics research. The global biologics market is expected to increase from $253.4 billion in 2020 to $420.5 billion by 2025. Therefore, the rising demand for biopharmaceuticals propels the growth of the fetal bovine serum market. Major players in the fetal bovine serum market are Sartorius AG, GE Healthcare, PAN- Biotech, Thermo Fisher Scientific Inc., Biowest, Bio-Techne, Rocky Mountain Biologicals Inc., Merck KGaA, TCS Biosciences Ltd., Bovogen Biologicals Pty Ltd., Tissue Culture Biologicals, Atlanta Biologicals Inc., Atlas Biologicals, Acess Biologicals, Animal Technologies Inc., Nucleus Biologics, Corning Incorporated, J R Scientific Inc., Cytiva, Axil Scientific Pte Ltd., and Moregate Biotech . Increasing collaborations between companies and research intuitions is a key trend gaining popularity in the fetal bovine serum market. Major companies are collaborating for increasing production capabilities, expanding market share and developing new products. For instance, US based GE Healthcare collaborated with New Zealand based Oritain for developing an independent test that can confirm the country of origin of fetal bovine serum (FBS) which would help biomanufacturing entities as FBS used in different countries pose different risk levels for virus contamination. Sartorius, a German-based life science research and biopharmaceutical company acquired Biological Industries for $53.67 million. Through this acquisition, Sartorius expanded cell culture media and complementing the product portfolio for the users in the growing advanced therapies market in the majority portion of Biological Industries. Biological Industries is an Israel-based chemical and biotechnology company that provides fetal bovine serum for mammalian cell culture. North America was the largest region in the fetal bovine serum market in 2022. Asia-Pacific recorded the fastest growth during the forecast period. The regions covered in the fetal bovine serum market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the Fetal Bovine Serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The fetal bovine serum market consists of sales of Ultra-low IgG, ES Cell, MSC and Exosome-Depleted. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The fetal bovine serum market research report is one of a series of new reports from The Business Research Company that provides fetal bovine serum market statistics, including fetal bovine serum industry global market size, regional shares, competitors with a fetal bovine serum market share, detailed fetal bovine serum market segments, market trends and opportunities, and any further data you may need to thrive in the fetal bovine serum industry. This fetal bovine serum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fetal and neonatal monitoring devices market are used to assess the fetal heart rate and contractions of the uterus during pregnancy and childbirth. The main equipment of fetal and neonatal monitoring devices and equipment are fetal and neonatal. Neonatal monitoring devices and equipment are used for the monitoring of various body parameters of the newborn. Portable or non-portable fetal and neonatal monitoring devices and equipment Fetal care equipment types are ultrasound devices, fetal dopplers, fetal MRI systems, fetal monitors, and fetal pulse oximeters. Neonatal care equipment types are infant warmers, incubators, convertible warmers and incubators, phototherapy equipment, respiratory devices, neonatal monitoring devices, and diagnostic imaging devices. The various end-users are hospitals, diagnostic centres, pediatric clinics, and ambulatory surgical centres. The global fetal and neonatal monitoring devices market is segmented - 1) By Equipment: Fetal, Neonatal 2) By End User: Hospitals, Diagnostic centers, Pediatric Clinics, Ambulatory Surgical Centers 3) By Portability: Portable, Non Portable 4) By Fetal Care Equipment Type: Ultrasound Devices, Fetal Dopplers, Fetal MRI Systems, Fetal Monitors, Fetal Pulse Oximeters 5) By Neonatal Care Equipment Type: Infant Warmers, Incubators, Convertible Warmers & Incubators, Phototherapy Equipment, Respiratory Devices, Neonatal Monitoring Devices, Diagnostic Imaging Devices The global fetal and neonatal monitoring devices market size will grow from $7.62 billion in 2022 to $8 billion in 2023 at a compound annual growth rate (CAGR) of 4.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of fetal and neonatal monitoring devices is expected to grow to $9.31 billion in 2027 at a CAGR of 3.9%. The increasing prevalence of preterm births and the low body weight of infants act as a factor driving the fetal and neonatal monitoring devices market growth. Preterm birth refers to the premature birth of a child before 37 weeks gestation period, which leads to poor health and growth, mental retardation, visual and hearing impairments, cerebral palsy, and others. According to World Health Organization (WHO), around 1 million babies die each year and preterm birth was found to be one of the top reasons for the deaths. According to the report by WHO, nearly 15 million babies are born preterm every year and this number is expected to have a continuous rise shortly. The increasing prevalence and need to reduce the infant mortality rates with improving healthcare conditions drives the fetal and neonatal monitoring devices market. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2021 the preterm birth rate in American women was 10.5%. Major players in the fetal and neonatal monitoring devices market are GE Healthcare, Fisher & Paykel Healthcare Limited, Philips Healthcare, Atom Medical Corporation, Natus Medical Incorporated, Analogic Corporation, Phoenix Medical Systems (P) Ltd., Becton Dickinson, Masimo Corporation, and Drägerwerk AG & Co. KGAA. The fetal and neonatal monitoring device market is restricted by stringent regulatory policies governing this market. The fetal and neonatal device manufacturers need to pass through several tests and requirements laid down by different regulatory bodies. Regulations like FDA's Center for Devices and Radiological Health (CDRH), NMPA regulations, EU directives lay down some stringent regulations for this equipment. The changes related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes lead to increased healthcare costs. For instance, according to a report by Ernst and Young, Fortune 500 companies are spending $7.8 billion to comply with GDPR. The GDPR is an EU law on the data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). Furthermore, the FDA is requesting more clinical data to support claims resulting in increased processing times of 510(k)s by over 55% over the last decade, thus delaying the operating cycle of manufacturers in this market. Fetal and neonatal monitoring device manufacturers are increasingly innovating and integrating technologies such as wireless technology with patient monitoring devices to efficiently diagnose and monitor fetuses and newborns. Wireless sensor technology such as biosensor monitoring devices, wireless fetal heart rate monitoring devices is multi-sensor systems implanted or embedded into the skin, consisting of a sensor that transmits data for real-time monitoring of a patient’s medical condition. For instance, the National Institute of Neurological Disorders and Stroke developed SARA, a scanning device that can detect fetal brain activity with the help of flashes of light transmitted through the mother's abdomen. Philips developed a new cordless fetal monitoring device that helps in ensuring the safety of the mother as well as the child without any inconvenience and risk. These technological innovations eliminate poor reception of observation and help caregivers in monitoring more efficiently. Hong Kong’s Department of Health, a regulatory body for fetal and neonatal monitoring devices of Hong Kong, sent a medical device safety alert to Guangzhou Sunray Medical Apparatus Co., Ltd., a medical device manufacturer, concerning its maternal and fetal monitor. The safety alert was sent as the Guangzhou Sunray maternal and fetal monitor was delivering inaccurate ultrasound-derived fetal heart rate recordings due to software-related issues. These devices impacted patients’ health with delayed intervention resulting in severe injury or death to the fetus. To reduce incidences associated with these devices MRHA sent a medical device safety alert to correct the device. Similarly, in January 2021, Medtronic PLC., received Class II recall notice from the Food and Drug administration for its Neonatal valves due to problematic design. The faulty device resulted in shunt malfunction in certain cases. Asia-Pacific was the largest region in the global fetal and neonatal monitoring devices market in 2022. North America was the second-largest region in the fetal and neonatal monitoring devices market report. The regions covered in the fetal and neonatal monitoring devices and equipment analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the fetal and neonatal monitoring devices market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The fetal and neonatal monitoring devices market consists of sales of instruments such as ultrasound devices, fetal dopplers, fetal MRI systems, fetal monitors, and fetal pulse oximeters. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The fetal and neonatal monitoring devices market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The fetal and neonatal monitoring devices market research report is one of a series of new reports from The Business Research Company that provides fetal and neonatal monitoring devices market statistics, including fetal and neonatal monitoring devices and equipment industry global market size, regional shares, competitors with a fetal and neonatal monitoring devices market share, detailed fetal and neonatal monitoring devices market segments, market trends and opportunities, and any further data you may need to thrive in the fetal and neonatal monitoring devices and equipment industry. This fetal and neonatal monitoring devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fertility drugs refer to a term used to describe medications that cause your body to release hormones that regulate or prompt ovulation, or the release of an egg from your ovary. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered orally, intravenously, subcutaneously, and intramuscularly to male and female patients. Subcutaneous administration refers to the process of injecting the drugs into the fatty tissue just beneath the skin. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The global fertility drugs market is segmented - 1) By Gender: Male, Female 2) By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular 3) By Type Of Drug: Prescription Fertility Drugs, Over-The-Counter Fertility drugs 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global drugs for infertility market size will grow from $2.93 billion in 2022 to $3.03 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global drugs for infertility is expected to grow to $3.30 billion in 2027 at a CAGR of 2.1%. The growth of the market for fertility drugs is driven by the increasing rates of infertility across the globe. Infertility is the inability to conceive after trying for 12 consecutive months. Fertility drugs are widely used to treat infertility in both men and women. The rising rates of infertility are attributed to physiological problems, hormone problems, and lifestyle or environmental factors. To treat infertility problems in women, fertility drugs are used to regulate their ovulation cycles, which affects the sale of these drugs. For instance, in September 2020, according to the World Health Organization (WHO), a Switzerland-based international public health organization, millions of people in the world who are of reproductive age will struggle with infertility, which will also have an effect on their families and communities. Worldwide, it is estimated that 48 million couples and 186 million people struggle with infertility. Hence, the rising cases of infertility across the globe are increasing the demand for fertility drugs, resulting in the fertility drug market growth. Major players in the fertility drugs market are Merck & Co., Ferring Pharmaceuticals, Bayer, Berlex Laboratories Inc., Janssen Pharmaceutical Inc., Pfizer, Novartis AG, Procter & Gamble Pharmaceutical, Zydus Pharma, LIVZON, Abbott, MSD, Sanofi S.A., Eli Lilly and Co., Serono, Inc., Novogyne Pharmaceuticals, and Takeda Pharmaceutical co. ltd. The side effects caused due to fertility drugs restricted the growth of the fertility drugs market. Fertility drugs can result in permanent as well as temporary side effects. Temporary side effects include bloating, headache, breast tenderness, upset stomach, hot flashes, and mood swings whereas the permanent side effects include multiple pregnancies, and ovarian hyperstimulation syndrome (OHSS). OHSS is a condition where the ovaries enlarge with fluids and may become life-threatening if left untreated. For instance, the intake of Clomid (clomiphene citrate), a fertility drug for women, can result in OHSS along with abnormal vaginal/uterine bleeding, breast tenderness or discomfort, headache, nausea, vomiting, diarrhea, flushing, blurred vision, or other visual disturbances. The fear of potential side effects of fertility drugs restricts the growth of the fertility drugs market. The companies in the fertility drugs market are focusing on the launch of self- administration fertility solutions for advanced infertility treatment. The self- administration fertility solution makes it easier and less painful for women to self-administer daily injections. For example, in August 2021, Merck Specialities, the healthcare business of Merck in India, launched Pergoveris Pen for advanced infertility treatment in India. This launch aims to fulfill unmet medical needs by providing an improved, convenient, and ready-to-use combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency. The Pergoveris Pen is a combination of a freeze-dried powder and solvent, reducing the probability of reconstitution errors. As a result, Pergoveris delivers with more precision and, hence, is more accessible to self-administration by patients during infertility treatment. In January 2020, Evotec SE, a Germany-based pharmaceutical company specialising in drug discovery and development, announced strategic partnerships with Bayer AG, a pharmaceutical and biotechnology company pioneering in the discovery, development, manufacturing, and commercialization of drugs. Under this collaboration, to develop a new cure and multiple clinical candidates for the treatment of polycystic ovary syndrome together, both businesses will offer drug targets and a wide array of high-quality technological platforms. North America was the largest region in the fertility drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global drugs for infertility market during the forecast period. The regions covered in the global fertility drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The fertility drugs market consists of sales of clomiphene citrate, gonadotropins, and metformin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The fertility drugs market research report is one of a series of new reports from The Business Research Company that provides fertility drugs market statistics, including fertility drugs industry global market size, regional shares, competitors with a fertility drugs market share, detailed fertility drugs market segments, market trends and opportunities, and any further data you may need to thrive in the fertility drugs industry. This fertility drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fertility treatment is a medical treatment provided to a man or a woman to increase their chances of bearing an offspring. It is used to treat infertile patients. Hormone and ovulation-supporting medicines are frequently used in fertility treatments, sometimes in conjunction with minor surgical procedures. The main product types of fertility are reagents, and equipment. A reagent is a material or compound that is added to a system to produce a chemical reaction or to determine whether or not a reaction occurred. The treatments are performed on female and male in fertility clinics, hospitals, surgical centers, and clinical research institutes. The global fertility treatments market is segmented - 1) By Product: Reagents, Equipment 2) By End-User: Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes 3) By Patient Type: Female, Male The global fertility treatments market size grew from $15.26 billion in 2022 to $16.48 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the fertility treatments is expected to grow from $22.77 billion in 2027 at a CAGR of 8.4%. The growth in the median age of first-time motherhood combined with change in lifestyle increased the difficulty of conceiving, increasing the demand for fertility treatment. The median age of first-time motherhood has increased all over the globe due to late marriages, contraceptive techniques, and an increase in the number of women who prioritize their careers over starting a family. In 2020, the average age of first-time mothers in America has risen from 21 to 26. Women in other developed countries are also deferring, with the typical first birth occurring at the age of 31 for new mothers. In this scenario, a growing number of women are opting for IVF treatments, which is expected to drive the fertility treatments market. Major players in the fertility treatment market are Apollo Hospitals Enterprise Ltd., Care Fertility Group, Genea Limited, The Johns Hopkins Health System Corp., Medicover Group, Monash IVF Group, Progyny Inc., Vitrolife, Carolinas Fertility Institute, OvaScience Inc., Xytex Cryo International, Merck KGaA, Cook Medical, CooperSurgical Inc., Instituto Bernabeu, INVO Bioscience, The Cooper Companies Inc., Virtus Health, CryoChoice LLC., Millendo Therapeutics Inc., FUJIFILM Irvine Scientific, LABOTECT GMBH, Fertility Focus, Olympus Corporation, Irvine Scientific sales Company Inc., and Ferring Pharmaceuticals. The high cost and low success rate of In vitro fertilization (IVF) treatment is a major factor that limits the growth of the fertility treatments market. In vitro fertilization is a fertilization process in which an egg is fertilized with sperm outside the body, in vitro. In vitro fertilization (IVF) treatment costs differ in many countries due to the lack of refund policies. Moreover, insurance companies usually do not cover infertility treatments. According to the American society of reproductive medicine, in the USA, the average cost of an IVF cycle is $12,400 and the average cost of an IVF cycle using fresh embryos is $8,158 with a median cost at $7,500. The rate of success of IVF treatments is only 28% to 35%, which decreases with the increase in woman's age. For example, for women, the success rate is 32.2% under 35 and 1.9% for women aged over 44. Thus, the high cost and low success rate of IVF treatment restrict the growth of the fertility treatment market. Development of new techniques to treat infertility using a human’s body is a key trend in the fertility treatments market. INVOcell is an IVF alternative that uses the woman’s body to support fertilization, thus eliminating the cost of a laboratory incubator. The INVOcell device is placed with the eggs and sperm in the vaginal cavity, allowing for the stability of the natural environment, pH, and gas to help in fertilization. INVOcell, which is made in Medford, Massachusetts by INVO Bioscience, costs around $6,800 including medication. Although IVF generated more quality embryos, the birth rates between IVF and INVOcell are similar. According to the journal of assisted reproduction and genetics, 12 out of 20 women gave birth to 15 babies in IVF including three sets of twins and 11 out of 20 women gave birth to 16 babies in INVOcell group including five sets of twins. In August 2022, CCRM Fertlity, an American fertility treatment company, acquired Institute for Reproductive Medicine & Sciences (IRMS) for an undisclosed amount. The acquisition would add world class proprietary reproductive medicine offerings to the CCRM’s portfolio and expand its footprint across 11 major metropolitan areas with 34 locations across the US and Canada. Institute for Reproductive Medicine and Science (IRMS) is a US-based fertility research and treatment company having its presence in major metropolitan areas. North America was the largest region in the fertility treatment market in 2022. Western Europe was the second largest region in the global fertility treatment market share. The regions covered in the global fertility treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The fertility treatment market includes revenues earned by entities by providing medicinal services, surgical services, and assisted services such as in vitro fertilization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The fertility treatment market research report is one of a series of new reports from The Business Research Company that provides fertility treatment market statistics, including fertility treatment industry global market size, regional shares, competitors with a fertility treatment market share, detailed fertility treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fertility treatment industry. This fertility treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Assisted reproductive technology is based on the surgical removal of eggs from women’s ovaries and then fusing them with men’s sperm in the laboratory to create embryos. These embryos are then inserted back into the woman’s body. ART uses donor eggs, donor sperm, or previously stored frozen embryos. Assisted reproductive technology (ART) is used for the treatment of infertility in either eggs or embryos. The main types of assisted reproductive technology are in-vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo replacement (FER), and others. In-vitro fertilisation (IVF) is a complicated operation that involves collecting eggs and fertilising them with sperm in a lab to create embryos. These embryos are subsequently implanted into women's reproductive organs. The different procedure types include fresh non-donor, fresh donor, frozen donor, frozen non donor, embryo or egg banking and is used in hospitals, fertility clinics, others. The global assisted reproductive technology market is segmented - 1) By Diagnosis: Ovulation Testing, Hysterosalpingography, Ovarian Reserve Testing, Genetic Testing 2) By Procedure Type: Fresh Non-Donor, Fresh Donor, Frozen Donor, Frozen Non-Donor, Embryo Or Egg Banking 3) By End-User: Hospitals, Fertility Clinics, Other End-Users The global assisted reproductive technology market size grew from $31.4 billion in 2022 to $37.56 billion in 2023 at a compound annual growth rate (CAGR) of 19.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The assisted reproductive technology market size is expected to grow to $75.64 billion in 2027 at a CAGR of 19.1%. The rising number of infertility cases is expected to foster the assisted reproductive technology market in the coming years. Infertility is defined as the failure to become pregnant after a year of frequent and unprotected intercourse. Infertility affects both men and women, and is typically diagnosed by the inability to conceive. Infertility is treated using assisted reproductive technology (ART). Fertility therapies that work with both a woman's egg and a man's sperm are included in this. For instance, according to the UCLA Health, a US based health system, in 2020 around 15% of couples in the world have trouble in conceiving. Infertile couples are increasingly turning to assisted reproductive technology (ART), which is growing at a rate of 5% to 10% every year. Therefore, the rising number of infertility cases drives the growth of the assisted reproductive technology market. Major players in the assisted reproductive technology market are Cooper Surgical Inc., Ferring B.V., Hamilton Thorne Ltd., Merck KGaA, Genea Limited, California Cryobank, European Sperm Bank, OvaScience Inc., Bloom IVF Centre, Vitrolife, FUJIFILM Irvine Scientific Inc., Nidacon International AB, Monash IVF Group Ltd., Cook Medical, INVO Bioscience Inc., Thermo Fisher Scientific, Boston Science Corporation, Anecova, Carolinas Fertility Institute, Microm Ltd. Technological advancements is a key trend gaining the popularity in the assisted reproductive technology market. Major companies operating in the assisted reproductive technology are focused on developing technological solutions to strengthen their position. For instance, in November 2020, NIPD Genetics, a Cyprus based biotechnology company launched Amfira PGT based on Target Capture Enrichment Technology. Amfira PGT is a preimplantation genetic test which can be employed during fertility treatment to improve the odds of becoming pregnant and giving birth to a healthy child. Amfira PGT can be used in In Vitro Fertilization (IVF) cycles to determine whether embryos are chromosomally normal (euploid) and have the best chance of culminating in a safe pregnancy and birth. In August 2021, Virtus Health Limited, an Australia-based company offering assisted reproductive technology acquired Adora Fertility and three-day hospitals from Healius Limited for $45.0 million. This acquisition will help Virtus health to strengthen its portfolio for in-vitro fertilization (IVF). Adora Fertility is an Australia-based company that provide assisted reproductive technology (ART) including IVF (In-vitro fertilisation) and ICSI (Intracytoplasmic Sperm Injection). Europe was the largest region in the assisted reproductive technology market in 2022. North America was the second-largest region in assisted reproductive technology market. The regions covered in the assisted reproductive technology (ART) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the assisted reproductive technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The assisted reproductive technology market includes revenues earned by entities by gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), and frozen embryo transfer (FET). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The assisted reproductive technology (ART) market research report is one of a series of new reports from The Business Research Company that provides assisted reproductive technology (ART) market statistics, including assisted reproductive technology (ART) industry global market size, regional shares, competitors with a assisted reproductive technology (ART) market share, detailed assisted reproductive technology (ART) market segments, market trends and opportunities, and any further data you may need to thrive in the assisted reproductive technology (ART) industry. This assisted reproductive technology (ART) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lateral Flow Immunoassay (LFIA) based rapid test is a simple technology-based diagnostic device that is used to determine the presence of a target such as pathogens or biomarkers in samples collected from the human body. These samples may include urine, saliva, blood, sweat and other fluids. The main techniques in lateral flow immunoassay-based rapid testing are competitive assay, sandwich assay, and multiplex detection assay. The competitive assay is used to assess the existence of a target, such as pathogens or biomarkers, in the samples. The applications are infectious disease, pregnancy and fertility, toxicology, and others that are used in hospitals and clinics, diagnostic laboratory, home care, and others. The global lateral flow immunoassay (LFIA) based rapid test market is segmented - 1) By Technique: Competitive Assay, Sandwich Assay, Multiplex Detection Assay 2) By End User: Hospital & Clinic, Diagnostic Laboratory, Home Care, Other End Users 3) By Application: Infectious Disease, Pregnancy & Fertility, Toxicology, Other Applications The global lateral flow immunoassay (LFIA) based rapid test market size is declined from $10.14 billion in 2022 to $9.19 billion in 2023 at a compound annual growth rate (CAGR) of -9.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global lateral flow immunoassay (LFIA) based rapid test market size is expected to decline to $7.32 billion in 2027 at a CAGR of -5.5%. The demand for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market. Point-of-care (POCT) testing is essential for rapid on-site diagnosis and treatment. The most important features for current POCT diagnostic systems are a quick analysis time with a test-to-answer format. Lateral flow immunoassays (LFIA) are widely used as POCTs due to their speed and precision, simplicity, and low cost. For instance, the recent outbreak of coronavirus disease (COVID-19) has increased the significance of these devices to rapid screening and surveillance. Acro Biotech COVID-19 Rapid POC CE-IVD is a lateral flow immunoassay that quantifiably assesses the existence of patient-generated IgG and IgM antibodies to SARS-CoV-2, the causative agent of novel coronaviral disease COVID-19. These antibodies may be detected in whole blood, serum, or plasma samples in the test cassette. OZO has developed three different variations of its products using the Latex Enhanced Lateral Flow Immunoassays (LFIAs) method for testing COVID-19. Therefore, the need for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market. Major players in the lateral flow immunoassay (LFIA) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Danaher Corporation, Siemens AG, Becton, Dickinson and Company, bioMérieux, Bio-Rad Laboratories, Thermo Fisher Scientific, QIAGEN NV, and Hologic Inc. Low sensitivity of Lateral Flow Immunoassay (LFIA) Based Rapid Test is expected to limit the market. The sensitivity of the test is mainly the ability of the test to correctly identify those with the disease, which is low for Lateral Flow Immunoassay (LFIA) Based Rapid Test compared to other methods that may, in some cases, require a re-test for confirmation. according to a study conducted by researchers, including those from the Harvard medical school in the USA and also the University of British Columbia, Canada. The medical databases and preprint servers were searched from January 1 to April 30, 2020, for studies measuring the sensitivity and specificity of the COVID-19 antibody test compared to the control test. It had been found that pooled sensitivities were consistently lower for the lateral flow immunoassay (LFIA) test compared to other test methods. The low level of sensitivity is anticipated to restrain the market growth for Lateral Flow Immunoassay (LFIA) based rapid test. Companies are collaborating to launch new products. In May 2020, Lateral Flow Diagnostic Company Mologic Ltd., which has teamed up with Biosure Ltd., the developer of the only CE-approved HIV home testing kit, to develop a COVID-19 antibody self-test. The companies combine Mologic's validated IgG lateral flow test strip with Biosure's test kit. In July 2020, MP Biomedicals Asia-Pacific Pte Ltd collaborated with a Singapore company A*STAR to create the ASSURE® SARS-CoV-2 IgG / IgM rapid antibody test kit to detect IgG and IgM antibodies in a person infected with SARS-CoV-2. The kit delivers precise results in very less time as less as 15 minutes and uses the lateral flow method. In April 2020, True Diagnostics, a leading US-based Point of Care (POC) company, partnered with Veravas and Infectolab Americas to create and distribute a fast, point-of-care immunoassay for SARS-CoV-2, the VeraTest SARS-CoV-2 IgA / IgG Fast Test will be developed to detect immunoglobulin A and immunoglobulin G antibodies to SARS-CoV-2 in the blood within 15 minutes. The test combines True Diagnostics, TrueDx lateral flow immunoassay technology with Veravas, VeraPrep clean, and VeraPrep capture technologies designed to remove cross-reaction antibodies and ensure the detection of only SARS-CoV-2-specific antibodies. Veravas is an emerging US-based diagnostic company. Infectolab Americas is a US-based laboratory specialized in lab testing for tick-borne disease. North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2022. Asia-Pacific was the second largest region in the global lateral flow immunoassay (LFIA) based rapid test market. The regions covered in the global lateral flow immunoassay (LFIA) based rapid test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the lateral flow immunoassay (LFIA) based rapid test market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. Lateral Flow Immunoassay (LFIA) based rapid test market consits of sales of conjugarte pads, nitrocellulose membrane and absorbent pad. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The lateral flow immunoassay (LFIA) based rapid test market research report is one of a series of new reports from The Business Research Company that provides lateral flow immunoassay (LFIA) based rapid test market statistics, including lateral flow immunoassay (LFIA) based rapid test industry global market size, regional shares, competitors with a lateral flow immunoassay (LFIA) based rapid test market share, detailed lateral flow immunoassay (LFIA) based rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the lateral flow immunoassay (LFIA) based rapid test industry. This lateral flow immunoassay (LFIA) based rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders. The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the genito-urinary drugs industry in the historic period. Pharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In December 2019, GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA ® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Major companies in the genito-urinary drugs market include Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. North America was the largest region in the genito-urinary market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global genito-urinary drugs market is segmented - 1) By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs